Citations

Clear

1792 citation(s) found for "Stephanie".

138. DIFFUSE ALVEOLAR HEMORRHAGE, PULMONARY NODULES AND INFILTRATES IN GRANULOMATOSIS POLYANGIITIS AND MICROSCOPIC POLYANGIITIS. A COHORT STUDY OF 736 PATIENTS
Garner, Stephanie , Rawn, Saara, Cox, Gerald, Carette, Simon , Koening, Curry L. , Langford, Carol A. , McAlear, Carol A. , Sreih, Antoine G. , Ytterberg, Steven R. , Pagnoux, Christian , Cuthbertson, David , Monach, Paul A. , Moreland, Larry W. , Seo, Philip , Specks, Ulrich , Merkel, Peter A. , Khalidi, Nader

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez059.015 Get It

Patients’ Medical and Psychosocial Experiences After Detection of a CDH1 Variant With Multigene Panel Testing
Hamilton, Jada G. , Brandt, Amanda , Brower, Jamie , Symecko, Heather , Christian, Stephanie N. , Harstad, Tricia, Offit, Kenneth , Long, Jessica M. , Salo‐Mullen, Erin E. , Couch, Fergus J. , Garber, Judy E. , Robson, Mark E. , Domchek, Susan M.

Mayo Clinic

JCO Precision Oncology | March 28, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-14

10.1200/po.18.00300 | PMID 31511843 Get It

PURPOSE Germline CDH1 pathogenic variants (PV) are associated with hereditary diffuse gastric cancer and lobular breast cancer. Although prevalence of CDH1 PV is low in the general population, detection of these variants is increasing with the growing use of multigene panel testing. Little is known about the experiences of individuals tested for CDH1 variants in the multigene panel testing era. METHODS Participants recruited from the Prospective Registry of Multiplex Testing completed a cross-sectional self-report survey regarding CDH1 genetic testing experiences, medical management, and psychosocial adaptation. RESULTS Discordance existed in interpretations of CDH1 results; 13.3% of cases had disagreements in variant classifications among commercial laboratories, and 21.4% had disagreements between participant self-report and ClinVar classification. Survey data were available from 57 individuals reporting either PV (n = 16) or variants of uncertain significance (VUS; n = 41). Those with PV were more likely than those with VUS to report receiving a recommendation for prophylactic gastrectomy, although only 40.0% of those with PV received this recommendation. Participants with VUS were less satisfied with their health care providers’ knowledge and reported less CDH1 knowledge, distress, and worry about discrimination. Participants with PV perceived greater breast cancer risks, but similar gastric cancer risks, as those with VUS. CONCLUSION Few individuals with CDH1 PV report receiving recommendations for prophylactic gastrectomy, and no differences in perceived gastric cancer risk were observed based on participants’ CDH1 results, suggesting serious unmet informational needs.
PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas
Caudle, Kelly E. , Gammal, Roseann S., Karnes, Jason H. , Afanasjeva, Janna, Anderson, Keri C. , Frazee, Erin N. , Beavers, C. , Bhat, Shubha , Birrer, Kara L., Ensor, Christopher R. , Flowers, Stephanie A. , Formea, Christine M. , George, Jomy, Gosser, Rena , Karaoui, Lamis R. , Kolpek, Jimmi Hatton , Leung, Jonathan G. , Maldonado, Angela Q. , Minze, Molly G. , Pulk, Rebecca , Shelton, Chasity M. , Sheridan, Maria , Smith, Michael A. , Soefje, Scott A. , Tellez‐Corrales, Eglis , Walko, Christine M. , Leung, Jonathan G , Soefje, Scott A , Chahine, Elias B. , Hébert, Mary F. , Lee, James C. , Sheridan, Maria, Cavallari, Larisa H.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | March 25, 2019 | Volume: 2 | Issue: 3 | Pages: 288-302

10.1002/jac5.1107 Get It

Clinical pharmacists have been incorporating precision medicine into practice for decades. Drug selection and dosing based on patient‐specific clinical factors such as age, weight, renal function, drug interactions, plasma drug concentrations, and diet are expected as part of routine clinical practice. Newer concepts of precision medicine such as pharmacogenomics have recently been implemented into clinical care, while other concepts such as epigenetics and pharmacomicrobiomics still predominantly exist in the research area but clinical translation is expected in the future. The purpose of this paper is to describe current and emerging aspects of precision medicine as it relates to clinical pharmacy across a variety of specialty areas of practice, with perspectives from the American College of Clinical Pharmacy Practice and Research Network membership.
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Andrews, Stephanie, Armand, Philippe , Davies, Marianne, Dunnington, David, Frigault, Matthew J. , Hoffner, Brianna, Lunning, Matthew A. , Mohindra, Nisha , Naidoo, Jarushka , Olszanski, Anthony J. , Oluwole, Olalekan O. , Patel, Sandip Pravin , Reddy, Sunil , Ryder, Mabel , Santomasso, Bianca , Shofer, Scott , Sosman, Jeffrey A. , Wahidi, Momen M. , Johnson-Chilla, Alyse, Scavone, Jillian L., Oluwole, Olalekan O , Naidoo, Jarushka , Olszanski, Anthony J , Ryder, Mabel , Bhatia, Shailender , Budde, Lihua E. , Costa, Luciano J. , Ernstoff, Marc S. , Hoimes, Christopher , Lacouture, Mario E. , Locke, Frederick L. , Wang, Yinghong

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 20, 2019 | Volume: 17 | Issue: 3 | Pages: 255-289

10.6004/jnccn.2019.0013 | PMID 30865922 Get It

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org .
Endoscopic posterior cricoid reduction: A surgical method to improve posterior glottic diastasis
Alarcón, Alessandro de , Zacharias, Stephanie R. C. , Oren, Liran , Luzan, Charles Farbos de , Tabangin, Meredith E. , Cohen, Aliza P., Roetting, Nicholas J., de Alarcón, Alessandro , Zacharias, Stephanie, Tabangin, Meredith , Fleck, Robert J.

Mayo Clinic

The Laryngoscope | March 19, 2019 | Volume: 129 | Issue: S2 | Pages: No page available

10.1002/lary.27833 | PMID 30887529 Get It

Objectives/HypothesisDescribe the preoperative evaluation of patients with glottic diastasis who are candidates for endoscopic posterior cricoid reduction (EPCR) and their perioperative and postoperative surgical and voice outcomes, and validate the aerodynamic benefit of EPCR using computation fluid dynamics (CFD)‐based modeling from computed tomography (CT) scans.Study DesignRetrospective case series.MethodsThirteen patients who underwent EPCR were followed from 2013 to 2017. They received a preoperative voice evaluation, microlaryngoscopy and bronchoscopy, dynamic voice CT (performed on patients seen from 2014 to study completion), and postoperative voice evaluation (n = 12). Postoperative inpatient days, complications, and postoperative endoscopic intervention were collected. To validate the aerodynamic benefit of EPCR, CFD modeling was carried out on one patient.ResultsThirteen patients (nine females, nine with intubation injury, and four with post–airway reconstruction dysphonia) underwent EPCR at a mean age of 11.0 years. The mean preoperative and postoperative Pediatric Voice handicap Index scores were 53.8 and 33.8, respectively (P = .006). Mean maximum phonation time preoperatively and postoperatively was 5.3 and 6.7, respectively (P = .04). Of eight patients who underwent preoperative CT imaging, all demonstrated a posterior gap. Modeling demonstrated a change in flow and pressure. The mean hospital stay was 2.4 days. Nine patients underwent postoperative endoscopic intervention, and one experienced a complication that resolved with intervention.ConclusionsPatients who underwent EPCR for dysphonia following intubation or airway reconstruction showed improvements in vocal efficiency, loudness, and perceived voice handicapping. Their hospital stay was brief, with few complications. CFD modeling corroborated these clinical findings. EPCR thus warrants consideration in the management of patients with posterior glottic diastasis.Level of Evidence4 Laryngoscope, 129:S1–S9, 2019
Genitourinary syndrome of menopause: in their own words—development of a new patient-reported outcome measure
Kling, Juliana M. , Kling, Juliana M , Faubion, Stephanie S.

Mayo Clinic

Menopause | March 19, 2019 | Volume: 26 | Issue: 4 | Pages: 335-336

10.1097/gme.0000000000001309 | PMID 30724847 Get It

A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer.
Bauman, Julie E. , Lim, Dean, Sukari, Ammar , Wagner, Stephanie A., Curtis, Kelly K., Gitlitz, Barbara J. , Price, Katharine A. , Wade, James L. , Villaflor, Victoria , Souza, Jonas A. de, Karrison, Theodore , Vokes, Everett E. , Worden, Francis P. , Adkins, Douglas R. , Rao, Krishna A , Stadler, Walter M. , Seiwert, Tanguy Y.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6060-6060

10.1200/jco.2015.33.15_suppl.6060 Get It

A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of
Lheureux, Stéphanie , Weberpals, Johanne I. , Hendrickson, Andrea E. Wahner , Olawaiye, Alexander , Mackay, Helen , Wilson, Michelle , Rodríguez-Freixinós, Víctor, Martín-Lorente, Cristina, Ward, Jacklyn, Chang, Karen, Wang, Lisa , Speers, Vanessa , Karakasis, Katherine, Bowering, Valerie , Chen, Alice P. , Fleming, Gini F. , Braña, Irene , Dhani, Neesha C. , Chang, Karen, Brenton, James D. , Oza, Amit M.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS5613-TPS5613

10.1200/jco.2015.33.15_suppl.tps5613 Get It